Pharmaceutical Executive: December 2024

Click the title above for a link to open the Pharmaceutical Executive December 2024 issue in an interactive PDF format.

Complementing our own industry trends and outlook coverage this month are a trio of diverse crystal-ball perspectives from guest thought leaders.

Margaret Keegan, the new CEO of Precision Medicine Group, is eager to elevate the profile of the expert-rich service provider and build it into an industry leader in next-gen drug development and commercialization support.

The biosimilars market in the US is on the rise, but barriers to greater adoption remain.

Unleashed demand over the past year characterizes the M&A picture in pharma.

With the Inflation Reduction Act now in flux, how will the government and industry respond?

How alternative direct-to-consumer models are changing the landscape for patient access.

The swell of AI-powered digital platforms puts future decision-making under the spotlight.

Why investing in people and training can help drugmakers deal with six pressing challenges in particular in the year ahead.

The importance of expanding your pharma sales forecasting horizon beyond the US. Learn how to effectively navigate country-specific regulatory red flags.

A look at the promise and opportunities from this new and advanced type of AI in transforming commercial planning and execution for life sciences companies.

Identifying the inflators and deflators, and the role all stakeholders play.

AI provides opportunities to bring people together—not replace them.

In today’s pharmaceutical market access landscape, payers are not the sole decision-makers in utilization management development.